Anifrolumab Asian PhIII Efficacy Study for Systemic Lupus Erythematosus (SLE)
| 适应症 | Active Systemic Lupus Erythematosus |
|---|---|
| 分期 | 3期 |
| 申办方 | AstraZeneca |
| 状态 | 已完成 |
| 受试者人数 | 277 人 |
| 干预（药物） | Anifrolumab |
| 开始日期 | 2021年9月13日 |
| 完成日期 | 2025年4月7日 |
| 结果公布日 | 2026年5月20日 |
摘要
The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of anifrolumab versus placebo in Asian participants with active systemic lupus erythematosus (SLE).
Difference in Proportion of Participants Who Are Responders Between Anifrolumab and Placebo
| Anifrolumab 300mg | 84 Participants |
|---|---|
| Placebo | 46 Participants |
| p-value | >0.999 |
|---|---|
| Rate difference (%) | 28.4 |
在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文
同一适应症的其他试验
- Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacok — Viatris Innovation GmbH
- Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With — Viatris Innovation GmbH
- A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2 — Hoffmann-La Roche
- Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults — Duke University
- Reducing Disparities in Medication Adherence in SLE — Duke University
- Using the Cholinergic Anti-Inflammatory Pathway to Treat Systemic Lupus Musculoskeletal Pa — Northwell Health